These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 17116235)
21. Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain. Hong W; Wang Z; Liu W; O'Malley TT; Jin M; Willem M; Haass C; Frosch MP; Walsh DM Acta Neuropathol; 2018 Jul; 136(1):19-40. PubMed ID: 29687257 [TBL] [Abstract][Full Text] [Related]
22. Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. Ryan TM; Roberts BR; McColl G; Hare DJ; Doble PA; Li QX; Lind M; Roberts AM; Mertens HD; Kirby N; Pham CL; Hinds MG; Adlard PA; Barnham KJ; Curtain CC; Masters CL J Neurosci; 2015 Feb; 35(7):2871-84. PubMed ID: 25698727 [TBL] [Abstract][Full Text] [Related]
23. Diversity of senile plaques in Alzheimer's disease as revealed by a new monoclonal antibody that recognizes an internal sequence of the Abeta peptide. Rábano A; Jiménez-Huete A; Acevedo B; Calero M; Ghiso J; Valdés I; Gavilondo J; Frangione B; Méndez E Curr Alzheimer Res; 2005 Oct; 2(4):409-17. PubMed ID: 16248846 [TBL] [Abstract][Full Text] [Related]
25. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease. Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683 [TBL] [Abstract][Full Text] [Related]
26. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517 [TBL] [Abstract][Full Text] [Related]
27. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). Viola KL; Velasco PT; Klein WL J Nutr Health Aging; 2008 Jan; 12(1):51S-7S. PubMed ID: 18165846 [TBL] [Abstract][Full Text] [Related]
28. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102 [TBL] [Abstract][Full Text] [Related]
30. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains. Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307 [TBL] [Abstract][Full Text] [Related]
31. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Klein WL Neurochem Int; 2002 Nov; 41(5):345-52. PubMed ID: 12176077 [TBL] [Abstract][Full Text] [Related]
33. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage. Ferrera D; Mazzaro N; Canale C; Gasparini L Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120 [TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. Hatami A; Albay R; Monjazeb S; Milton S; Glabe C J Biol Chem; 2014 Nov; 289(46):32131-32143. PubMed ID: 25281743 [TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies against large oval aggregates of Aβ1-42. Shimizu T; Yoshimune K; Komoriya T; Akiyama T; Ye X; Kohno H J Biosci Bioeng; 2013 Feb; 115(2):216-20. PubMed ID: 23041139 [TBL] [Abstract][Full Text] [Related]
36. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. De Felice FG; Velasco PT; Lambert MP; Viola K; Fernandez SJ; Ferreira ST; Klein WL J Biol Chem; 2007 Apr; 282(15):11590-601. PubMed ID: 17308309 [TBL] [Abstract][Full Text] [Related]
37. An "epitomic" analysis of the specificity of conformation-dependent, anti-Aß amyloid monoclonal antibodies. Reyes-Ruiz JM; Nakajima R; Baghallab I; Goldschmidt L; Sosna J; Mai Ho PN; Kumosani T; Felgner PL; Glabe C J Biol Chem; 2021; 296():100168. PubMed ID: 33298522 [TBL] [Abstract][Full Text] [Related]
38. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. Savelieff MG; DeToma AS; Derrick JS; Lim MH Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056 [TBL] [Abstract][Full Text] [Related]
39. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944 [TBL] [Abstract][Full Text] [Related]
40. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Kim HD; Jin JJ; Maxwell JA; Fukuchi K Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]